BridgeBio Pharma, Inc.(BBIO)Stock Analysis

BBIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BridgeBio Pharma, Inc. (BBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BBIO at 31.7/100 on a 32-signal composite quality model, placing it at rank #2,301 of 2,879 stocks — the bottom half of the AI-ranked universe. BBIO scores in the top quartile across revenue growth (93.2). Areas of concern include balance sheet strength (1.5) and free cash flow (6.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BridgeBio Pharma, Inc. reports quarterly revenue of $194.5M, net income of $-166.6M, free cash flow of $-197.3M. Top institutional holders of BBIO by reported 13-F value include BlackRock,, Kohlberg Kravis Roberts & Co. L.P., JANUS HENDERSON GROUP PLC, based on the most recent SEC filings. BBIO trades on the Nasdaq exchange and files with the SEC under CIK 1743881. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BridgeBio Pharma, Inc. directly from SEC EDGAR. BridgeBio Pharma, Inc.'s 13F Pro composite quality score has ranged between 7 and 78 since 2021, currently 31.7 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.